11 research outputs found
Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases – should we think about revising the current treatment guidelines in selected patients?
OBJECTIVES: To refresh clinical diagnostic and therapeutic dilemmas in patients presenting with hepatocellular cancer (HCC) and to report a rare success of systemic polichemotherapy in metastatic HCC. METHODS: Case report of a patient with successfully resected HCC although initially deemed inoperable according to current guidelines, and who was successfully treated by systemic polichemotherapy after development of metastatic disease, resulting in a sustained complete remission. RESULTS: We describe a 71-year-old female with HCC initially treated by atypical liver resection, although not amenable to initial surgery according to current treatment guidelines, which resulted in 6 months disease-free interval. After development of pulmonary metastases, the patient was treated by systemic polichemotherapy, due to local unavailability of novel biologic agents. After 3 months of chemotherapy biochemical remission was confirmed, and after 10 months of active treatment complete radiological remission was verified according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, now exceeding 9 months in duration. CONCLUSION: There is an increasing body of evidence that criteria for surgical interventions in HCC should be revised and expanded, and our case is an example of such an approach. Although novel biologic therapies are not widely available in all regions of the world due to their cost, currently there are no hard recommendations for use of chemotherapy in such areas. Since this is a large problem in clinical practice, we conclude that chemotherapy should be offered to selected patients of good performance status if novel agents are unavailable
THE FIRST WAVE OF THE COVID-19 PANDEMIC AND ITS IMPACT ON THE LEVEL OF DISTRESS IN PATIENTS WITH BREAST CANCER, A MULTICENTRIC STUDY
Background: Information on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), later termed coronavirus
disease (COVID-19), first emerged by the end of 2019. As the pandemic spread, cancer patients were immediately recognized as a
high-risk population with regard to COVID-19 infection. Moreover, epidemiological measures, like social distancing and lockdowns,
additionally burdened patients with cancer. Even outside pandemic breast cancer patients are prone to psychological distress with
prevalence ranging approximately 20-40%. This multicentric study aimed to examine the impact of COVID-19 pandemic on the level
of distress among breast cancer patients in Croatia while the first wave of COVID-19 pandemic.
Subjects and methods: Fife hundred forty-five breast cancer patients were offered to participate in the study. A total of two
hundred and one patient, with disease stages ranging I-IV, completed the questionnaire. The questionnaire consisted of disease and
socio-demographic characteristics followed by the Distress Thermometer and a problem list. The cut off value of 4 was used to
define the high level of distress within Distress Thermometer.
Results: High distress level was reported in 54.2% of patients. The most significant problems reported by the participants of our
study affected emotions, causing worry, sadness, depression, fear, and nervousness. Additionally, specific practical problems
emerged (e.g., child care, housing, and work/school), most probably partly due to the lockdowns and social distancing. Interestingly
enough, none of the socio-demographic or disease characteristics were linked to the level of distress.
Conclusions: During first wave of COVID-19 pandemic more than half of breast cancer patients, undergoing active oncologic
treatment, experienced a high level of distress. Therefore, distress driven by the COVID-19 pandemic should be promptly addressed
and additional psychological and social support, targeting specific practical and emotional problems, should be provided for those
patients. All the more so as global COVID-19 pandemic far exceeded the duration of the first wave
THE FIRST WAVE OF THE COVID-19 PANDEMIC AND ITS IMPACT ON THE LEVEL OF DISTRESS IN PATIENTS WITH BREAST CANCER, A MULTICENTRIC STUDY
Background: Information on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), later termed coronavirus
disease (COVID-19), first emerged by the end of 2019. As the pandemic spread, cancer patients were immediately recognized as a
high-risk population with regard to COVID-19 infection. Moreover, epidemiological measures, like social distancing and lockdowns,
additionally burdened patients with cancer. Even outside pandemic breast cancer patients are prone to psychological distress with
prevalence ranging approximately 20-40%. This multicentric study aimed to examine the impact of COVID-19 pandemic on the level
of distress among breast cancer patients in Croatia while the first wave of COVID-19 pandemic.
Subjects and methods: Fife hundred forty-five breast cancer patients were offered to participate in the study. A total of two
hundred and one patient, with disease stages ranging I-IV, completed the questionnaire. The questionnaire consisted of disease and
socio-demographic characteristics followed by the Distress Thermometer and a problem list. The cut off value of 4 was used to
define the high level of distress within Distress Thermometer.
Results: High distress level was reported in 54.2% of patients. The most significant problems reported by the participants of our
study affected emotions, causing worry, sadness, depression, fear, and nervousness. Additionally, specific practical problems
emerged (e.g., child care, housing, and work/school), most probably partly due to the lockdowns and social distancing. Interestingly
enough, none of the socio-demographic or disease characteristics were linked to the level of distress.
Conclusions: During first wave of COVID-19 pandemic more than half of breast cancer patients, undergoing active oncologic
treatment, experienced a high level of distress. Therefore, distress driven by the COVID-19 pandemic should be promptly addressed
and additional psychological and social support, targeting specific practical and emotional problems, should be provided for those
patients. All the more so as global COVID-19 pandemic far exceeded the duration of the first wave
Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine - A metastatic disease 17 Years after complete surgical resection
Primary spinal melanomas are extremely rare lesions. In 1906, Hirschberg reported the first primary spinal melanoma, and since then only 40 new cases have been reported. A 47-year-old man was admitted suffering from low back pain, fatigue and loss of body weight persisting for three months. He had a 17-year-old history of an operated primary spinal melanoma from T7-T9, which had remained stable for these 17 years. Routine laboratory findings and clinical symptoms aroused suspicion of a metastatic disease. Multislice computed tomography and magnetic resonance imaging revealed stage-IV melanoma with thoracic, abdominal and skeletal metastases without the recurrence of the primary process. Transiliac crest core bone biopsy confirmed the diagnosis of metastatic melanoma. It is important to know that in all cases of back ore skeletal pain and unexplained weight loss, malignancy must always be considered in the differential diagnosis, especially in the subjects with a positive medical history. Patients who have back, skeletal, or joint pain that is unresponsive to a few weeks of conservative treatment or have known risk factors with or without serious etiology, are candidates for imaging studies. The present case demonstrates that complete surgical resection alone may result in a favourable outcome, but regular medical follow-up for an extended period, with the purpose of an early detection of a metastatic disease, is highly recommended
Impact of complementary and alternative medicine (CAM), religiosity, and evidence-based medicine (EBM) in advanced cancer patients.
Symptomatic cardiac metastases of breast cancer 27 years after mastectomy: a case report with literature review - pathophysiology of molecular mechanisms and metastatic pathways, clinical aspects, diagnostic procedures and treatment modalities.
Metastases to the heart and pericardium are rare but more common than primary cardiac tumours and are generally associated with a rather poor prognosis. Most cases are clinically silent and are undiagnosed in vivo until the autopsy. We present a female patient with a 27-year-old history of an operated primary breast cancer who was presented with dyspnoea, paroxysmal nocturnal dyspnoea and orthopnoea. The clinical signs and symptoms aroused suspicion of congestive heart failure. However, the cardiac metastases were detected during a routine cardiologic evaluation and confirmed with computed tomography imaging. Additionally, this paper outlines the pathophysiology of molecular and clinical mechanisms involved in the metastatic spreading, clinical presentation, diagnostic procedures and treatment of heart metastases. The present case demonstrates that a complete surgical resection and systemic chemotherapy may result in a favourable outcome for many years. However, a lifelong medical follow-up, with the purpose of a detection of metastases, is highly recommended. We strongly call the attention of clinicians to the fact that during the follow-up of all cancer patients, such heart failure may be a harbinger of the secondary heart involvement
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy
Despite huge advances in medicine, glioblastoma multiforme (GBM) remains a highly lethal, fast-growing tumour that cannot be cured by currently available therapies. However, extracranial and extraneural dissemination of GBM is extremely rare, but is being recognised in different imaging studies. To date, the cause of the GBM metastatic spread still remains under discussion. It probably develops at the time of intracranial progression following a surgical procedure. According to other hypothesis, the metastases are a consequence of spontaneous tumour transdural extension or haematogenous dissemination. We present a case of a 59-year-old woman with symptomatic leptomeningeal and intramedullary metastases of GBM who has been previously surgically treated with primary subtotal resection and underwent a repeated surgery during adjuvant radiotherapy and chemotherapy with temozolomide. Today, the main goal of surgery and chemoradiotherapy is to prevent neurologic deterioration and improve health-related quality of life. With this paper, we want to present this rare entity and emphasise the importance of a multidisciplinary approach, a key function in the management of brain tumour patients. The prognosis is still very poor although prolongation of survival can be obtained. Finally, although rare, our case strongly suggests that clinicians should be familiar with the possibility of the extracranial spread of GBM because as treatment improvements provide better control of the primary tumour and improving survival, metastatic disease will be increasingly encountered
Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy.
Currently used diagnostic criteria in different endemic (Balkan) nephropathy (EN) centers involve different combinations of parameters, various cut-off values and many of them are not in agreement with proposed international guidelines. Leaders of EN centers began to address these problems at scientific meetings, and this paper is the outgrowth of those discussions. The main aim is to provide recommendations for clinical work on current knowledge and expertise. This document is developed for use by general physicians, nephrologists, urologist, public health experts and epidemiologist, and it is hoped that it will be adopted by responsible institutions in countries harboring EN. National medical providers should cover costs of screening and diagnostic procedures and treatment of EN patients with or without upper urothelial cancers